7月11日，美好医疗今日收盘18.72元，上涨3.83%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到29.78倍，创28天以来新低，总市值106.49亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均52.06倍，行业中值37.22倍，美好医疗排 名第66位。 股东方面，截至2025年6月30日，美好医疗股东户数12487户，较上次增加119户，户均持股市值35.28万 元，户均持股数量2.76万股。 最新一期业绩显示，2025年一季报，公司实现营业收入2.96亿元，同比5.05%；净利润5187.50万元，同 比-10.62%，销售毛利率39.28%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13美好医疗29.7829.273.02106.49亿行业平均 52.0649.724.58107.83亿行业中值37.2238.112.4752.18亿1九安医疗10.3010.410.81173.78亿2英科医疗 10.8811.730.97171.88亿3新华医疗14.4413.391.1892.58亿4振德医疗15.4114.530.9855.95亿5奥美医疗 15. ...

公司基本信息 | 产业别 | 电气设备 | | --- | --- | | A 股价(2025/7/7) | 100.80 | | 深证成指(2025/7/7) | 10435.51 | | 股价 12 个月高/低 | 168.33/34.12 | | 总发行股数(百万) | 240.20 | | A 股数(百万) | 206.20 | | A 市值(亿元) | 207.85 | | 主要股东 | 深圳前海兆威 | | | 金融控股有限 | | | 公司(35.44%) | | 每股净值(元) | 13.43 | | 股价/账面净值 | 7.51 | | | 一个月 三个月 一年 | | 股价涨跌(%) | -3.5 -11.0 130.0 | 近期评等 2025 年 07 月 08 日 赵旭东 H70556@capital.com.tw 目标价(元) 118 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 产品组合 | | | | 微型传动系统 | | 63.3% | | 精密零件 | | 30.7% | | 精密模具及其他 | | 6.0% | 机构投资者占流通 A ...

7月4日，美好医疗今日收盘18.05元，上涨1.69%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到28.71倍，总市值102.68亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13美好医疗28.7128.232.92102.68亿行业平均 51.0548.784.55107.12亿行业中值36.6236.522.5051.67亿1九安医疗10.2610.380.81173.21亿2英科医疗 10.4711.290.93165.45亿3新华医疗14.4313.381.1892.52亿4奥美医疗15.3215.011.5755.35亿5山东药玻 15.3915.431.77145.53亿6振德医疗15.4714.580.9856.17亿7康德莱15.7315.741.3033.89亿8维力医疗 16.4917.141.9337.60亿9九强生物16.4915.332.0281.66亿10奥泰生物16.6117.511.3452.96亿11安杰思 17.6117.812.1352.26亿12安图生物18.8317.982.42214.74亿 来源：金融界 从行业市盈率排名来看，公司 ...

| | 无锡微研有限公司 | | | --- | --- | --- | | | 资产交割过渡期损益的 | | | | 专项审计报告 | | | 索引 | 页码 | | | 专项审计报告 | | 1-3 | | 公司财务报表 | | | | — | 合并资产负债表 | 1-2 | | — 合并利润表 | | 3 | | — 财务报表附注 | | 4-65 | | | 专项审计报告 | | XYZH/2025NJAA2B0251 无锡微研有限公司 宁波精达成形装备股份有限公司： 一、 审计意见 我们审计了无锡微研有限公司（以下简称无锡微研公司）过渡期财务报表，包括 2025 年 4 月 30 日（过渡期末）合并资产负债表，2024 年 5 月 1 日至 2025 年 4 月 30 日（过 渡期）合并利润表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照附注二财务报表的编制基础编制， 公允反映了无锡微研公司 2025 年 4 月 30 日财务状况以及 2024 年 5 月 1 日至 2025 年 4 月 30 日（过渡期）经营成果。 二、 形成审计意见的基础 我们按照中国注册会计师审计准则的规定 ...

Company Overview - Meihao Medical closed at 17.25 yuan on June 26, down 1.09%, with a rolling PE ratio of 27.44 times and a total market capitalization of 9.813 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 49.45 times and a median of 35.92 times, placing Meihao Medical at the 63rd position in the industry ranking [1] Shareholding Structure - As of the first quarter of 2025, 30 institutions held shares in Meihao Medical, including 24 funds, 4 others, and 2 insurance companies, with a total shareholding of 42.1394 million shares valued at 1.23 billion yuan [1] Business Operations - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, including home ventilator components, cochlear implant components, and other medical product components [1] - The company is recognized as a national high-tech enterprise and a national intellectual property advantage enterprise, as well as a champion in a specific manufacturing sector in Guangdong Province [1] Financial Performance - In the first quarter of 2025, Meihao Medical reported revenue of 296 million yuan, a year-on-year increase of 5.05%, and a net profit of 51.875 million yuan, reflecting a year-on-year decrease of 10.62%, with a gross profit margin of 39.28% [1]

国金证券股份有限公司 关于深圳市泛海统联精密制造股份有限公司关联方为公司 向金融机构申请授信额度 提供反担保暨关联交易的核查意见 国金证券股份有限公司（以下简称"保荐机构"）作为深圳市泛海统联精密制 造股份有限公司（以下简称"统联精密"或"发行人"）首次公开发行股票并在科创 板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所 上市公司自律监管指引第 11 号——持续督导》《上海证券交易所科创板股票上 市规则》以及《科创板上市公司持续监管办法（试行）》等法规的有关规定，对 公司控股股东、实际控制人杨虎及其配偶王小林为公司（公司指"统联精密"或 此次申请融资授信额度的两家子公司"深圳市泛海统联精密模具有限公司"、 "深 圳市泛海统联智能制造有限公司"）向金融机构申请授信额度提供反担保暨关联 交易事项进行了审慎核查，发表如下意见： 一、本次申请授信额度的基本情况 公司为拓宽融资渠道，同时降低融资成本，公司拟向深圳市高新投小额贷款 有限公司（以下简称"高新投小额贷款"）申请融资授信额度。其中深圳市泛海 统联精密模具有限公司（以下简称"精密模具"）以其名下有权处分的一项专利 作为质押担保，向高新投小 ...

Group 1: Investor Relations Activity Overview - The investor relations activity was conducted online on June 16 and June 18, 2025, involving various institutional investors [3][5] - Participating institutions included West Securities, Dongwu Securities, and several well-known funds and investment companies [3][5] Group 2: Acquisition of Tongyihe - The company introduced the acquisition of 51% of Tongyihe Precision Technology Co., Ltd., a recognized player in precision mold manufacturing [5][6] - Tongyihe specializes in precision molds and components, with major clients including global automotive parts companies such as Faurecia and Magna [5][6] Group 3: Competitive Advantages of Tongyihe - Tongyihe holds 20 patents, including 3 invention patents and 17 utility model patents, related to its core business [8] - The company has established long-term relationships with major clients, ensuring stable customer resources [8][9] - Tongyihe has a leading market position in the domestic precision mold industry, particularly in hydraulic precision molds [8][9] Group 4: Synergies from the Acquisition - The acquisition will enable customer resource sharing and market collaboration, expanding the customer base for both companies [10] - Supply chain integration will optimize procurement processes and reduce costs by leveraging the combined purchasing power [10][11] - The transaction aims to enhance technical collaboration, improving the overall metal forming process and service offerings [10][11] Group 5: Business Growth and New Client Development - The company plans to deepen its focus on the suspension business, with ongoing projects and collaborations with various automotive clients [11][12] - New technologies, such as the second and third generation welding ring production lines, are expected to enhance production efficiency and reduce costs [11][12]

近期，A股固态电池概念再度升温，多股连续上涨。6月10日晚，多家公司发布异动公告，披露公司固 态电池相关业务情况。 继6月9日涨停后，6月10日，甬金股份再度"一字涨停"，市值攀升至71亿元。6月10日晚间，甬金股份对 公司涉及的相关概念予以澄清。 其表示，公司主营业务为冷轧不锈钢板带的研发、生产和销售。业务下游主要应用于家用电器、建筑装 潢、厨电厨具等行业，不涉及"固态电池"相关产品。请投资者注意风险，理性决策，审慎投资。 公司表示，其子公司东莞致宏精密模具有限公司（以下简称"致宏精密"）专注于精密模具及零配件产品 的研发、设计、生产和销售。致力于为下游锂电池生产企业、新能源设备制造企业提供能满足不同生产 工艺、产品性能及应用需求的系列极片自动裁切高精密模具、高精密模切刀等产品及解决方案。公司不 直接生产固态电池。 德新科技还表示，致宏精密所生产的精密模具及零配件产品可用于固态电池的生产，2024年度用于固态 电池生产的产品销售收入占公司全年营业收入比例不足1％。鉴于公司股票价格短期涨幅较大，可能存 在非理性炒作。 6月6日、9日、10日，德新科技股价连续三个交易日涨停，股价创去年11月以来新高。6月10日 ...

证券代码：603088 证券简称：宁波精达 公告编号：2025-033 宁波精达成形装备股份有限公司关于 向特定对象发行股份募集配套资金实施情况暨新增股份股本变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ? 发行数量和价格 股票种类：人民币普通股（A 股） 发行股票数量：32,258,064 股 发行股票价格：5.58 元/股 ? 预计上市时间 本次募集配套资金的新增股份已于 2025 年 6 月 9 日在中国证券登记结算有 限责任公司上海分公司办理完成登记手续。 本次发行新增股份在其限售期满的次一交易日在上海证券交易所上市交易 （预计上市时间如遇法定节假日或休息日，则顺延至其后的第一个交易日）， 限售期自股份发行完成之日起开始计算。 ? 资产过户情况 本次募集配套资金不涉及资产过户情况，发行对象以现金认购。 如无特别说明，本公告中涉及有关单位及术语的简称与上市公司同日在上海 证券交易所网站（http://www.sse.com.cn）披露的《宁波精达成形装备股份有 限公司发行股份及支付现金购 ...

Group 1 - Yihui Lithium Energy plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength and international brand image, aiming to expand its international market presence and global competitiveness [1] - The issuance will consider the interests of existing shareholders and the conditions of domestic and international capital markets, with the timing and window for issuance to be determined later [1] - The plan requires approval from the shareholders' meeting and relevant regulatory authorities, making future developments noteworthy [1] Group 2 - Defang Nano announced a capital increase for its subsidiary Defang Chuangyu, introducing strategic investors such as Guoxin Capital and Chengdu Industrial Investment, with a total investment of 100 million yuan [2] - After the capital increase, Defang Nano's ownership in Defang Chuangyu will decrease to 42.84%, but the company will maintain control [2] - The transaction does not involve related party transactions or constitute a major asset restructuring, and does not require approval from regulatory authorities, showcasing the company's flexibility in capital market operations [2] Group 3 - Dexin Technology clarified that it does not directly produce solid-state batteries, but its subsidiary provides precision molds and products for lithium battery production, which can be used in solid-state battery manufacturing [3] - Sales revenue from products used in solid-state battery production accounts for less than 1% of the company's total revenue for 2024, yet the company emphasizes the importance of every customer [3] - The announcement serves as a reminder for investors to rationally assess market trends and be aware of investment risks [3]